We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,092

Pharma in brief - blinded expert evidence favoured: Court dismisses PM(NOC) application for ciclesonide
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 19 2015

Takeda Canada Inc. and Takeda GMBH (Takeda) brought an application under section 6 of the PM(NOC) Regulations for an order prohibiting


Pharma in brief - SCC invited to revisit key patent issues: standard of review of claims construction and the patentability of methods of medical treatment
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 14 2015

Bayer Inc. (Bayer) distributes a combination oral contraceptive tablet under the brand name YAZ (drospirenone and ethinylestradiol


Allegations of obviousness of three patents found justified
  • Borden Ladner Gervais LLP
  • Canada
  • May 18 2015

In a proceeding pursuant to the Patented Medicines (Notice of Compliance) Regulations, the Court was asked to consider three patents. Apotex alleged


Pharma in brief - Generic v. Generic PM(NOC) application dismissed for non-infringement
  • Norton Rose Fulbright Canada LLP
  • Canada
  • April 21 2015

In a recently published Public Judgment and Reasons, Justice Gleason dismissed Teva Canada Innovation and Teva Pharmaceutical


Court of Appeal raises issues of construction and medical treatment that should be considered by a higher court in future cases
  • Borden Ladner Gervais LLP
  • Canada
  • May 18 2015

Both Bayer and Cobalt appealed from the Court’s judgment. Both appeals were addressed by the Court of Appeal in this decision. The Court of Appeal


Proactive pharma patent enforcement on Canadian drug combos
  • Bereskin & Parr LLP
  • Canada
  • May 14 2015

The Canadian Patented Medicine (Notice of Compliance) Regulations ("NOC Regulations") allow a patent owner to apply to Federal Court to keep a


Ontario Court of Appeal conclusively dismisses generic’s unjust enrichment arguments in section 8 case
  • Borden Ladner Gervais LLP
  • Canada
  • May 18 2015

Apotex has brought a case against Lilly pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations (the NOC Regulations). As part


Federal Court of Appeal suggests need for Supreme Court to consider standard of review on claims construction and patentability of methods of medical treatment
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 12 2015

The Federal Court of Appeal (FCA) in Cobalt v. Bayer has explicitly called into question two central principles of Canadian patent law: the standard


Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer


PM(NOC) proceedings: Teva defeats VELCADE cancer treatment patent
  • McCarthy Tétrault LLP
  • Canada
  • April 17 2015

In reasons dated February 26, 2015, Justice Barnes dismissed Janssen's application for an order prohibiting the Minister of Health from issuing a